These Melanoma Patients Got a Vaccine Made for Their Own Tumors. 2 Years Later, 82% Are Still Cancer-Free

An apparent leak prompted Merck and Moderna to release the full trial results ahead of schedule, but investors puzzlingly greeted the good news by sending the companies’ stock prices down.